This is a StreetInsider.com Premium Only Page

(GMAB) – Press Releases

Apr 22, 2024 03:30 AM Transactions in Connection with Share Buy-back Program Genmab

Apr 16, 2024 06:24 AM Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024

Apr 15, 2024 04:07 AM Transactions in Connection with Share Buy-back Program Genmab

Apr 8, 2024 05:44 AM Transactions in Connection with Share Buy-back Program

Apr 3, 2024 01:34 AM Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio

Apr 2, 2024 03:24 AM Transactions in Connection with Share Buy-back Program

Mar 25, 2024 09:30 AM Transactions in Connection with Share Buy-back Program

Mar 18, 2024 05:49 AM Completion of share buy-back program

Mar 15, 2024 08:16 AM Genmab Announces Initiation of Share Buy-Back Program

Mar 13, 2024 04:58 PM Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Mar 13, 2024 04:52 PM Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab

Mar 11, 2024 05:42 AM Transactions in connection with share buy-back program

Mar 4, 2024 01:10 PM Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Mar 4, 2024 04:29 AM Transactions in connection with share buy-back program

Mar 1, 2024 06:04 PM Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Feb 29, 2024 10:48 AM Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Feb 27, 2024 03:42 PM Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Feb 27, 2024 07:45 AM U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma

Feb 26, 2024 07:45 PM U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma

Feb 26, 2024 05:21 AM Transactions in connection with share buy-back program

Feb 23, 2024 05:50 PM Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Feb 23, 2024 05:35 PM Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab

Feb 19, 2024 04:40 AM Transactions in connection with share buy-back program

Feb 15, 2024 06:00 AM Notice to Convene the Annual General Meeting of Genmab A/S

Feb 14, 2024 02:09 PM Genmab Files Annual Report with the U.S. Securities and Exchange Commission

Feb 14, 2024 11:41 AM Genmab Announces Initiation of Share Buy-Back Program

Feb 14, 2024 11:02 AM Genmab Publishes 2023 Annual Report

Jan 25, 2024 02:22 PM Grant of Restricted Stock Units and Warrants to Employees in Genmab

Jan 23, 2024 06:24 AM Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2023

Jan 22, 2024 06:40 PM Genmab Announces Decision in Arbitration Appeal under License Agreement with Janssen

Jan 9, 2024 06:45 AM TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer

Jan 9, 2024 06:45 AM TIVDAK® Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer

Jan 3, 2024 12:55 AM Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Jan 2, 2024 09:52 AM Genmab to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 12, 2023 07:00 AM Genmab to Hold 2023 R&D Update and ASH Data Review Meeting

Dec 9, 2023 12:00 PM New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)

Dec 9, 2023 12:00 PM New Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL)

Dec 5, 2023 05:26 PM Capital Increase in Genmab as a Result of Employee Warrant Exercise

Nov 21, 2023 04:45 PM Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Nov 21, 2023 04:42 PM Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab

Nov 9, 2023 09:14 AM Major Shareholder Announcement

Nov 9, 2023 05:00 AM Genmab to Present at Jefferies London Healthcare Conference

Nov 8, 2023 11:09 AM Major Shareholder Announcement

Nov 7, 2023 11:01 AM Genmab Announces Financial Results for the First Nine Months of 2023

Oct 22, 2023 10:30 AM TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial

Oct 17, 2023 06:22 AM Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2023

Sep 28, 2023 02:38 PM Grant of Restricted Stock Units and Warrants to Employees in Genmab

Sep 25, 2023 05:55 AM EPKINLY™ (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory (R/R) Large B-C

Sep 12, 2023 02:04 PM Capital Increase in Genmab as a Result of Employee Warrant Exercise

Sep 4, 2023 03:00 PM Seagen and Genmab Announce TIVDAK® (tisotumab vedotin-tftv) Improved Overall Survival in Patients With Recurrent or Metastatic Cervical Cancer Compared With Chemotherapy Alone